secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001213900-25-027106
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio presents MINDFuL Phase II baseline data at AD/PD 2025; topline results due June 2025
--------------------------------------------------------------------------------

- Poster details baseline demographics of 208 patients (44% MCI, 56% mild AD) enrolled in MINDFuL Phase II trial of XPro1595.
- 69.2% of patients are APOE ε4 carriers; 64.4% met inclusion criteria for more than one inflammation biomarker.
- Primary endpoint is change from baseline in Early and Mild Alzheimer's Cognitive Composite (EMACC) score; topline results expected June 2025.
- Patients randomized 2:1 to XPro 1.0 mg/kg or placebo once weekly for 23 weeks; screen failure rate was 72%.
- Baseline characteristics show similarity to Phase III trials; no efficacy data disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/0001213900-25-027106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025027106/ea0236644-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-027106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer